The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Jul 06, 2026
Snapshot (as of Jul 06, 2026): Novo Nordisk A/S (NVO) pays a $11.70 annual dividend ($1.22 monthly), yielding 3.58% at $50.43/share. Next ex-dividend date 2026-03-30. 8 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 3.58%
Annual Dividend: $11.70 per share
Payout Ratio: 42.5%
Ex-Dividend Date: 2026-03-30
Dividend Frequency: monthly
Sector: Healthcare
Years of Dividend History: 45
Novo Nordisk A/S dividend investors are looking at a pharmaceutical company built around diabetes and obesity care, with products ranging from insulin pens to GLP-1 therapies sold across Europe, North America, and Asia. The current yield is 3.58%, with a trailing annual dividend rate of $11.70 per share paid monthly. The most recent dividend was $1.2174 per share, with an ex-dividend date of March 30, 2026. A beta of 0.36 means NVO stock moves far less than the broader market, which suits income investors who prioritize low volatility over high yield.
Novo Nordisk A/S pays out 42.5% of earnings as dividends, a payout ratio classified as moderate (40-60%). That level leaves meaningful earnings retained within the business, and NVO's two core divisions, Diabetes and Obesity Care and Rare Disease, address chronic conditions that generate recurring demand for therapies and medical devices like insulin pens. Novo Nordisk A/S dividend safety faces its most credible pressure from currency exposure, given that the company operates across Europe, the Middle East, Africa, Asia, and North America, meaning a stronger Danish krone or weaker dollar directly affects the per-share dollar amount paid to U.S. holders.
Novo Nordisk A/S dividend history shows a CAGR of 18.0% per year from 2010 to 2025. Per-share payments grew from $0.1407 to $1.6830 over that window (2026 is a partial year and excluded from the CAGR calculation). The largest single-year jump in the window was 85.7% in 2016, though the data also contains at least one year-over-year decline exceeding 5%, so growth has not been linear. For income investors, an 18.0% annualized growth rate means the dividend has roughly doubled every four years on average.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +27.6% | $0.81 (2022) | $1.68 (2025) |
| 5-Year | +20.9% | $0.65 (2020) | $1.68 (2025) |
| 10-Year | +16.0% | $0.38 (2015) | $1.68 (2025) |
NVO stock fits dividend investors who want meaningful income growth from a pharmaceutical business anchored in chronic disease treatment. The yield sits in the moderate (2-4%) range at 3.58%, which is above the stock's own 5-year average of 3.29%, so current buyers are getting a slightly better entry yield than the historical norm. The 42.5% payout ratio leaves room for further increases without straining earnings. The trade-off is that the dividend is paid in a foreign currency context and has shown at least one historical decline, so the per-share dollar amount is not immune to fluctuation. Eight consecutive years of increases and an 18.0% CAGR define the growth side of the equation.
| Payment Date | Amount per Share |
|---|---|
| 2026-03-30 | $1.2174 |
| 2025-08-18 | $0.5840 |
| 2025-03-31 | $1.0990 |
| 2024-08-16 | $0.5130 |
| 2024-03-22 | $0.9300 |
| 2023-08-18 | $0.4420 |
| 2023-03-24 | $0.5945 |
| 2022-08-12 | $0.2920 |
| 2022-03-25 | $0.5180 |
| 2021-08-16 | $0.2785 |
| Year | Total Dividends |
|---|---|
| 2026 | $1.2174 |
| 2025 | $1.6830 |
| 2024 | $1.4430 |
| 2023 | $1.0365 |
| 2022 | $0.8100 |
Project income from NVO with the NVO dividend calculator or track your full portfolio with the dividend tracker.